Journal of Cancer Science and Research
Open Access
ISSN: 2576-1447
+44 1478 350008
ISSN: 2576-1447
+44 1478 350008
Veena M Singh
Inc., 5810 Nancy Ridge Drive San Diego, CA, 92121
United States
Case Report
Clinical Utility of Target Selector™ ctDNA Testing: Detection of EGFR Mutations via Liquid Biopsy Enabled Targeted Therapy Selection for Patients with Advanced NSCLC
Author(s): Veena M Singh, Rodrigo Erlich and Cecile Rose T VibatVeena M Singh, Rodrigo Erlich and Cecile Rose T Vibat
Background: Molecular profiling of tumors provides information key for devising personalized therapeutic strategies for managing disease in cancer patients. A liquid biopsy is emerging as a sensitive means to evaluate biomarker status without the complications and costs associated with surgical biopsies, particularly for patients unable or unwilling to undergo invasive procedures.
Materials and Methods: Patient blood specimens were collected in Biocept’s proprietary Blood Collection Tubes for liquid biopsy testing in Biocept’s CLIA-certified, CAP-accredited laboratory. Dual Circulating Tumor Cell (CTC) and circulating tumor DNA (ctDNA) platforms were utilized to detect ALK or ROS1 gene rearrangements by FISH, or EGFR mutations, respectively.
Results: Described are three metastatic NSCLC patients for which liq.. View More»
DOI:
10.4172/2576-1447.1000113